Biomarker-driven patient stratification is the foundation of modern precision medicine and the primary mechanism through which pharmaceutical companies are improving clinical trial success rates, reducing development costs, and achieving premium pricing. The companion diagnostic landscape has matured from a specialized oncology tool into a broadly deployed precision medicine strategy spanning immunology, rare disease, neuroscience, and cardiovascular medicine. FDA approved more than 50 companion diagnostics in the period 2020-2025.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Companion Diagnostic Co-Development
• Oncology Biomarkers
• Liquid Biopsy in Clinical Development
• Multi-Cancer Early Detection
• Biomarkers Beyond Oncology
• AI in Biomarker Discovery
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Companion Diagnostic Co-Development
4. Oncology Biomarkers
5. Liquid Biopsy in Clinical Development
6. Multi-Cancer Early Detection
7. Biomarkers Beyond Oncology
8. AI in Biomarker Discovery
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Program and Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
